Goodwin Procter Advised SixPeaks Bio on Acquisition by AstraZeneca for Up to $300 Million
The Global Law firm, Goodwin's Life Sciences team advised SixPeaks Bio in its acquisition by AstraZeneca
Goodwin Procter Advised SixPeaks Bio on Acquisition by AstraZeneca for Up to $300 Million
The Global Law firm, Goodwin's Life Sciences team advised SixPeaks Bio in its acquisition by AstraZeneca for a total potential consideration of up to $300 million. The transaction includes an upfront payment of $170 million, $30 million payable in two years, and up to $100 million contingent on future regulatory milestones.
The acquisition, which closed in late October, supports AstraZeneca's strategic focus on developing next-generation obesity treatments that prioritize muscle preservation alongside weight reduction.
SixPeaks Bio is developing a pipeline of best- and first-in-class medicines for healthy weight loss. The company emerged from Versant Ventures’ Ridgeline Discovery Engine in the Basel Technology Park.
The Goodwin Procter deal team was led by Robert E. Puopolo (Partner), Andrew Harrow (Partner), and Michael Grainger (Associate), Hattie Muncey (Associate), Amine Assouad (Associate), Heidi McNally (Associate), Matthew Lee (Associate), and Morag Peberdy (Partner), Kathleen Kean (Partner), and Christopher Zhong (Associate), Lucy Sharples (Associate) , anti-trust advice from Arman Oruc (Partner), and Kevin Walsh (Counsel), and Andrew Jensen (Associate), and tax advice from Dan S. Karelitz (Partner), and Dulcie Daly (Partner), and Nathan Alexandere Langford (Associate).
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.